November 14, 2022
We exhibited our product GenPad at MEDICA 2022, a medical equipment exhibition held in Düsseldorf, Germany from November 14th to 17th.
MEDICA (International Medical Equipment Exhibition) is the world's largest medical equipment trade fair that had been held in Germany since 1969. Following "MEDICA 2021", which was held in real life for the first time in two years last year, we have exhibited a booth again this year.
At MEDICA 2021, there were 3,033 exhibitors from 46,000 visitors from 150 countries, but in 2019, before the spread of the new coronavirus, more than 120,000 visitors and more than 5,500 participating companies and the world's largest traditional exhibition.
This year, 4 Japanese staffs, including CEO Dr. Hayashizaki, and local staff participated. Compared to the last’s booth, the number of visitors this year exceeded that of the previous year, made our booth standing out from the crowd. The CEO gave a lecture at the local venue on 16th, the third day.
Our page on MEDICA Website:
May 24, 2022
Mirai Genomics is happy to announce that the GenPad Diagnostic Solution (GenPad Analyzer and Test Kit for SARS-CoV-2 RNA Detection in Biological Material Using PCR Method) received the CE mark on May 24, 2022, bringing reliable COVID-19 testing and clearing it for sale and distribution in the European Union (EU).
February 16, 2022
The second SmartAmp PCR test laboratory was opened at Tokyo Dome City on February, 14.
Tokyo residents can get a free COVID test at SmartAmp Station till 6 March (depending on period set by Tokyo Metropolitan Government).
November 18, 2021
On November 15-18, 2021, Mirai Genomics took part in the world forum MEDICA 2021 presenting its diagnostic solutions.
MEDICA is the leading international trade fair in the world, attracting more than 5,600 exhibitors and 120,000 visitors from over 66 countries each year.
In the last 40 years, Medica has been expanding its horizons, and every year the whole healthcare industry gathers together to meet international experts and market leaders.
November 4, 2021
The Nikkan article provides information on several diagnostic devices. GenPad gives the best result in terms of sensitivity and at the same time has the advantage of portability and compactness.
A palm-sized device has been designed for on-the-spot COVID-19 testing. Based on the PCR SmartAmp technology, it offers high level of sensitivity and specificity. It also allows for building up a cluster of up to 96 devices connected to one PC.
See more here.
October 29, 2021
The Yomiuri Shimbun, one of the five national newspapers in Japan, published an article about GenPad. On October 28, 2021, GenPad was presented to the general public in Japan as a small-sized device able to test COVID-19 in just 40 minutes.
The device size is 11 cm in height, 12 cm in length, and 4 cm in width. The cartridge with the collected saliva sample is inserted into the device and the results are ready in 40 minutes.
Until now, during the analysis, samples with saliva were transported to a special institution where additional devices are located. When using GenPad, this is not required anymore.
On November 6, GenPad was tested with Japanese Fencing Federation athletes on the eve of a fencing tournament throughout Japan.
See more here.
On June 28, 2021, Kanagawa Prefecture governor Yuji Kuroiwa held a press conference announcing two COVID-19 technologies that have been collaboratively developed by Mirai Genomics and Kanagawa Prefecture.
The first technology is PEM reagents, reagents able to identify simultaneously the infection presence and the SARS-CoV-2 mutant strains by PCR method.
The second technology is GenPad, a cutting-edge POC solution, with 1 step to get the result with 99.9% accuracy in 40 minutes using own licensed SmartAmp® PCR technology.
Kanagawa Prefecture will continue to support these technologies that greatly contribute to the prevention of the infection spread in the prefecture.
On July 10, 2021 Mirai Genomics took part in the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). ECCMID is one of the most comprehensive and influential congresses in the field and brings together more than 14,000 colleagues from all over the world.
The session of Mirai Genomics hosted Prof. Hayashizaki, CEO of Mirai Genomics and a well-established scientist known worldwide as a leading specialist in genome research and covered the best practices use for COVID-19 testing, underlining GenPad as a POC diagnostic method with a superior testing accuracy.
You could watch the full version of the session here.